Metastatic Breast Cancer Highlights From ESMO 2019

Sibylle Loibl, MD, PhD


October 22, 2019

Three presidential symposium presentations highlight the studies in metastatic breast cancer from the European Society for Medical Oncology (ESMO) 2019 Annual Meeting.

Overall survival (OS) results from the MONARCH 2 and MONALEESA-3 trials confirmed OS benefits from the cyclin-dependent kinase 4/6 (CDK4/6) inhibitors abemaciclib and ribociclib in hormone receptor–positive, human epidermal receptor–negative (HR+/HER2-) metastatic breast cancer. Discussant Sibylle Loibl, MD, PhD, director of the German Breast Group, Frankfurt, Germany, comments on the data of these two trials. 

The two other studies from the presidential symposium focused on triple-negative breast cancer (TNBC). Dr Loibl discusses the BROCADE 3 study, which assessed carboplatin plus a taxane with or without veliparib as first-line therapy in BRCA mutation carriers with TNBC. The study showed a statistically significant but modest improvement in progression-free survival.

Dr Loibl concludes that the OS data from MONARCH 2 and MONALEESA-3 studies confirm that CDK4/6 inhibition is "here to stay" in HR+/HER2- breast cancer, and that PARP inhibition plus chemotherapy in BRCA mutation carriers with TNBC improves progression-free survival.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.